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ABSTRACT OF DISSERTATION 
 
 
 
SHAME, GUILT, AND KNOWLEDGE OF HPV IN WOMEN RECENTLY 
DIAGNOSED WITH HPV-RELATED CERVICAL INTRAEPITHELIAL NEOPLASIA 
(CIN) 
 
The current study investigated the relationships between state shame, guilt, and disease 
knowledge in women recently diagnosed with cervical intraepithelial neoplasia (CIN) 
caused by the human papillomavirus (HPV).  Recent research has indicated that diagnosis 
of HPV can elicit negative self-directed affect, including persistent experiences of shame. 
Studies have also shown that knowledge of HPV is low in the general population, even 
though it is the most common sexually transmitted infection. It is important to understand 
how shame affects those with HPV because shame is related to a decline in important 
immune parameters that may be essential in HPV clearance. A sample of young women 
(ages 18-28) recently diagnosed with HPV were given measures of shame and guilt-
proneness, state shame and guilt, depression, impact of diagnosis, and HPV knowledge. 
A comparison group of women diagnosed with infectious mononucleosis caused by the 
Epstein-Barr Virus (EBV) were also given these measures.  It was predicted that women 
diagnosed with HPV would have higher levels of shame and guilt than women diagnosed 
with EBV.  It was also predicted that disease knowledge would moderate negative affect 
in women with HPV, where increases in HPV knowledge would neutralize feelings of 
shame and guilt.  The results of this study supported the first hypothesis: women with 
HPV experienced more shame and guilt than women with EBV. Shame largely mediated 
the relationship between diagnosis of HPV and depression, as well as HPV and distress, 
but these relationships were not significant for guilt. The hypothesis that disease 
knowledge would moderate feelings of shame was not supported in this study. Because of 
the biological and psychological consequences of shameful experiences, research should 
continue to measure factors that may predict shame after diagnosis of HPV. 
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Section One: Introduction 
Cervical intraepithelial neoplasia (CIN), also commonly known as cervical 
dysplasia, is an abnormal growth of squamous cells on the surface of the cervix.  If left 
untreated, a small percentage of women with CIN will develop cervical squamous cell 
carcinoma (Agorastos et al., 2005). The major cause of CIN development is infection 
with the Human Papillomavirus (HPV), with types 16 and 18 implicated in most cases of 
cervical cancer (Bosch et al., 2003). HPV is now recognized as the most common 
sexually transmitted infection (STI), with estimates of the prevalence of the disease 
ranging from 14-90% (Revzina et al., 2005). Despite the high prevalence of HPV, 
research has shown that knowledge of HPV biology and transmission is relatively low 
among the general population (Baer et al., 2000; Kahn et al., 2007).  
Although HPV is biologically linked to the development of cervical cancer 
(Bosch et al., 2002), there are also psychosocial consequences that arise from being 
diagnosed with HPV. Studies have shown that diagnosis is often associated with anxiety, 
distress, shame, and concerns about sexual relationships (Kahn et al., 2007: Maissi et al., 
2004). Perceptions of social threat (i.e., threats to one’s social self-esteem or acceptance), 
such as diagnosis of an STI, can produce negative self-evaluative emotions such as shame 
and can have a detrimental impact on immune parameters (Dickerson et al., 2004). 
Additionally, prolonged feelings of shame and guilt have been associated with 
immunological declines in disease populations (Weitzman et al., 2004: cited in Dickerson 
et al., 2004). Because cellular immune responses have been associated with regression of 
CIN, and shameful emotions have been linked to immunological declines, shame and 
guilt experiences may be very important to study in populations diagnosed with HPV or 
CIN.  
The primary aim of the current study was to compare shame and guilt in female 
college students recently diagnosed with cervical intraepithelial neoplasia (CIN) to a 
comparison group recently diagnosed with infectious mononucleosis (IM) caused by 
exposure to the Epstein-Barr virus (EBV). Epstein-Barr virus is a comparable infection in 
regards to prevalence and immunosuppression, yet there is little social stigma associated 
with IM diagnosis. A second aim of the study was to explore whether knowledge of the 
disease is related to lower levels of shame and guilt in HPV patients.  
HPV: A Common Disease 
Human papillomavirus (HPV) is a virus transmitted via skin to skin contact that 
causes either genital warts or cervical abnormalities. However, some types of HPV never 
present any infectious symptoms. There are over 100 different types of the virus that have 
been identified, and HPV is now the most common sexually transmitted infection (STI) 
in the United States (Revzina et al., 2005). One research study estimated that at any given 
time, 28.6% of women ages 14-59 are infected with HPV (Dunne et al., 2007). Of these 
women, it was estimated that around half are infected with the high-risk types of HPV 
(e.g., types 16 and 18) that have the highest chance of developing into cervical cancer 
(Bosch et al., 2003). According to the Centers for Disease Control (CDC, 2008), 80% of 
women will be infected with at least one type of HPV by the time they reach the age of 
50.  
The HPV Prognosis 
Low-risk types of HPV can cause genital warts (i.e., condylomata acuminate), 
which are benign skin growths on the surface of the genital area. Individuals presenting 
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with genital warts are most likely infected with types 6 or 11, which are thought to cause 
up to 90% of benign genital skin growths (Greer et al., 1995). The types of HPV that 
cause genital warts are deemed “low-risk” because they are unrelated to the development 
of genital cancer. Treatment for genital warts usually involves removal of the warts via 
liquid nitrogen cryosurgery. In some cases, warts are treated with topical cream or by 
laser cauterization (Sheinfeld et al., 2006). 
Other strains of HPV, deemed “high-risk” types, can cause cancer of the genital 
region of both males and females. Women with HPV that are at risk for cervical cancer 
first develop CIN, commonly known as cervical dysplasia, which presents as abnormal 
squamous cell growth on the surface of the cervix (Agorastos et al., 2005).  CIN is graded 
according to how far the abnormal cell growth spans the epithelium of the cervix. CIN1, 
known as grade I, corresponds to a low grade squamous intraepithelial lesion (LSIL), and 
is confined to the basal one-third of the epithelium. CIN2, known as grade II, corresponds 
to high grade squamous intraepithelial lesion (HSIL) or moderate dysplasia, and is 
confined to the basal two-thirds of the epithelium. CIN3, known as grade III, also 
corresponds to HSIL and often referred to as severe cervical dysplasia. CIN3 spans more 
than two-thirds of the epithelium and can involve the entire thickness of the cervix. CIN3 
is also sometimes referred to as cervical carcinoma in situ, which is related to the 
development of invasive cervical cancer (Park et al., 1998).  
According to the American Cancer Society (ACS, 2010), 11,270 women in the 
U.S. will be diagnosed with cervical cancer this year. Of these women, it is estimated that 
approximately 3,870 of them will die of the disease. The ACS has stated that regular 
cervical cancer screenings that begin at age 18 or at the onset of sexual activity can 
greatly reduce the risk of dying from cervical cancer.  
CIN Prevention, Detection, and Treatment 
Prevention. The use of condoms may not offer full protection from HPV due to 
the fact that HPV is spread through direct skin to skin contact. However, research has 
shown that the use of condoms is associated with decreased risk of HPV contraction and 
cervical cancer (Steiner, et al., 2006). In one study, HPV infection occurred in 37.8% of 
women whose partners used condoms in all cases of sexual intercourse and 89.3% in 
women whose partners reported using condoms less than 5 percent of the time (Winer et 
al., 2006).  
In 2006, the FDA approved a vaccine for the prevention of cervical cancer. The 
vaccine, known as Gardasil, is a substance containing human papillomavirus-like 
particles (VLP’s) that produce an antibody response preventing infection with four types 
of HPV (Lowy et al., 2006). Gardasil protects against HPV types 6 and 11, as well as 16 
and 18, which are thought to produce 90% of genital warts cases and 70% of cervical 
cancer cases, respectively. The vaccine is given in a series of three injections over the 
course of six months. The cost of the vaccine is 120 dollars per injection, totaling 360 
dollars for the full vaccine course. Although this vaccine can lower the risk of developing 
HPV related cervical cancer, this vaccine does not protect against all HPV types (Lowy et 
al., 2006). Moreover, the cost of the vaccine may be a deterrent in individuals from lower 
income families. Cervarix, a new bivalent vaccine for HPV types 16 and 18, is currently 
under FDA review. Unlike Gardasil, this vaccine would protect against cervical cancer 
but not genital warts (Harper, 2008). 
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Detection. Papanicolaou “pap” smears are the most common means of detecting 
CIN and pre-cancerous lesions on the cervix. Since the mid 1990’s, a liquid based 
monolayer cytology technique for pap tests has become increasingly popular. This test 
involves scraping cells from the outer opening of the cervix and placing them in a vial 
containing a liquid medium for preservation. The cells are then processed into a thin cell 
layer, stained, and examined under a microscope by a pathologist. This technique has 
been shown to have a sensitivity rate (i.e., correctly identified cell abnormalities in 
women who truly have these abnormalities) of between 61-66% and a specificity rate 
(i.e., correctly identified negative cell abnormalities in women who  truly do not have 
these abnormalities) of between 82-91% (Kulasingam, et al., 2002). Once abnormal cells 
are detected, women can undergo a colposcopy procedure where the cervical tissue is 
illuminated and magnified, allowing for a sample of the tissue to be removed for further 
pathological evaluation to determine the severity of the abnormality (ASCCP, 2008). 
Although a colposcopy procedure is relatively low risk, it is often painful and can cause 
bleeding and severe cramping.  
Treatment. For many women, HPV is suppressed by the immune system and 
never leads to the development of CIN or cervical cancer (Bollen et al., 1999). The 
regression of HPV is suggested to occur as a result of a cell-mediated immune response 
(Scott et al., 1999). This response involves T helper type 1 (Th1) cells that produce 
different types of immunoregulatory cytokines following exposure to an antigen. These 
cytokines upregulate tumor immunity and prevent T helper 2 (Th2) cells from producing 
cytokines that inhibit tumor immunity (Alcocer-Gonzoles et al., 2006; Jensen et al., 
2007).  Following established infection with HPV, research has shown that T-
lymphocytes that infiltrate the cervical epithelium, such as CD4+, may also be associated 
with the regression of HPV related cervical lesions (Coleman et al., 1994).  
Several surgical techniques are used to treat CIN that has been determined to be 
HSIL grade II or III (often via colposcopy procedure, Aerssens et al., 2008) including 
cone biopsy, cyrotherapy, laser evaporation, and loop electrosurgical excision procedure 
(LEEP). A LEEP procedure involves the cauterization of the surface of the cervix with an 
electrical current transmitted through a wire loop. LEEP is generally performed in an 
outpatient setting with local anesthetic. LEEP may have less symptom burden than other 
surgical treatments for resecting CIN cells, but may still cause some hemorrhage or 
cramping after treatment (Nuovo et al., 2000).  Aerssens and collegues found that after 
treatment with cyrotherapy or LEEP, HPV clearance rates were 80-90% in CIN patients 
after two years. These results suggest that women infected with HPV have treatment 
options that may dramatically reduce their risk of developing cervical cancer in the 
future. 
Psychosocial Effects of HPV/CIN Diagnosis 
Diagnosis of HPV or HPV-related CIN has significant medical implications, but 
less is known about the psychosocial and behavioral aspects of diagnosis (Kahn et al., 
2007). Reactions to diagnosis of HPV may include anger, anxiety, depression, concerns 
about sexual relationships, and feelings of stigmatization (Kahn et al., 2007; Maissi et al., 
2004). Feelings of shame have also been implicated as emotional reactions to diagnosis 
of HPV. Clark and colleagues (1996) found that two-thirds of HPV infected individuals 
in their sample (n =468) felt significant feelings of shame as a result of their diagnosis, 
and one-third of these individuals continued to experience these feelings after one year. 
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Furthermore, they suggested that HPV patients are dissatisfied with the amount of 
emotional support and information provided by their healthcare practitioners.  
Although HPV is a common disease, factual knowledge of HPV transmission, 
prevention, and etiology seems to be low in the general population. Tiro et al. (2007) 
found that in their sample of U.S. women ages 18-75 (n = 1,248), 40 percent had never 
heard of HPV. Moreover, of those women who had heard of HPV, over half of them were 
unaware that the virus caused cervical cancer.  One study by Maissi et al. (2004) found 
that a significant number of HPV patients in their sample did not understand their test 
results. The authors suggest that anxiety and distress may be reduced after diagnosis if 
healthcare practitioners provide clear and salient information about HPV to patients. 
Without adequate knowledge of HPV risk, etiology and transmission, diagnosis of the 
disease may cause significant and prolonged shame, confusion, anxiety, and frustration.   
There are inconsistencies in the literature about whether or not HPV knowledge 
has increased since the Gardasil vaccine was commercially introduced to the public in 
2006. Several studies have shown that many individuals are still generally under-
educated about the effects of HPV (Goldsmith et al., 2007; Tiro et al., 2007; Walsh, 
2008). However, a recent study by Ragin and colleagues (2009) found that more than 82 
percent of their sample was aware that HPV caused cervical cancer. These results may 
give the impression that HPV knowledge is improving, but the authors did find that more 
specific knowledge of HPV was lacking in their sample. For example, only 18 percent of 
their sample knew that the types of HPV that caused genital warts were different than the 
types of HPV that caused cervical cancer. Taken together, these results suggest that 
although HPV awareness may be improving, factual knowledge of HPV may still be 
limited in the general population. .  
Shame, Guilt, and Immune Function in HPV/CIN 
Shame vs. guilt. Shame and guilt have been labeled “self-conscious” emotions 
that involve reflective thinking about oneself (Eisenberg, 2000). Shame and guilt have 
been identified as distinct emotions that differentially affect emotional and physical 
health. Although both emotions are negatively self-evaluative, they differ in the way 
negative self-relevant events are construed and have very different implications for one’s 
global self-concept. Shame contains both internal (i.e., how one sees the self) and 
external (i.e., how he or she believes others see the self) components (Gilbert, 1998). 
Shameful experiences involve the entire self as the focus of evaluation and often include 
feelings of powerlessness and worthlessness (Tangney & Dearing, 2002). Shame involves 
negative self appraisal that is broad, enduring, and directly related to one’s view of the 
self that stretches beyond the behavior that sparked the emotional experience. In contrast, 
guilt involves scrutiny of one’s specific negative behavior, not one’s global self (Taylor, 
1985). Experiences of guilt may involve tension, regret, and remorse over a behavior but 
do not generalize to the entire self (Tangney et al., 1996). It is important to distinguish 
between these two overlapping emotions because guilt has shown to be mostly adaptive, 
whereas shame in particular has been associated with maladaptive functioning. Research 
suggests that guilt may foster moral behavior (Tangney and Dearing, 2002), whereas 
shame is often psychologically maladaptive and is related to anger, personal distress, 
anti-social behavior, psychosis, and reduced empathy for others (for a review, see Ayfer 
& Yagmurlu, 2008). Research has also indicated that shame, and not guilt, may be 
strongly related to depression (Orth, Berking, & Burkhardt, 2006). In a study with 149 
 
5 
adults undergoing marital separation, Orth and colleagues found shame had a strong, 
unique effect on depression but that shame-free guilt did not. It was discovered through 
subsequent meditational tests that shame elicits periods of event-related rumination, 
which in turn contributed to depressive symptomology. This finding may be particularly 
relevant to HPV diagnosis, as shameful emotions may be largely responsible for the 
strong association found between diagnosis and depression.  
 Shame is often the outcome of situations that involve threats to one’s perceived 
social status or acceptance (Dickerson et al., 2004). Moreover, shame involves situations 
where individuals feel their negative self is exposed to others in the form of either real or 
imagined audiences (Tangney et al., 1996). Being diagnosed with a sexually transmitted 
infection such as HPV can create these situational conditions. For example, an HPV 
positive woman may experience feelings of internal worthlessness, but she may also feel 
that her social acceptance is threatened when deciding whether to tell her partner about 
her diagnosis. She may feel that she will be rejected by her current or future partners and 
will be forever plagued with concerns about sexual relationships. She may also feel that 
society will evaluate her negatively for belonging to a stigmatized group of individuals 
who have been diagnosed with an STI. Perceived negative evaluation and rejection by 
others are feelings that have been expressed in previous studies with women diagnosed 
with HPV (Kahn et al., 2007).   
Shame and immune function. Experiences of shame and guilt, similar to those that 
may happen upon HPV diagnosis, are also related to compromised immune functioning. 
Shame has been shown to be associated with increases in cortisol activity (Gruenewald et 
al., 2004) and proinflammatory cytokine activity (Dickerson et al., 2004) in acute 
situations. Moreover, several studies have shown that negative self-evaluative emotions 
can cause changes in CD4+ T helper cells in disease populations over the long term. 
Segerstrom et al. (1996) found that self-blame was related to faster declines in these cells 
over a 1 ½ year follow up of HIV positive men. Similarly, Weitzman et al. (2004) (as 
cited in Dickerson et al., 2004) found that persistent feelings of shame and guilt in HIV 
positive men over 7 year follow-up predicted significant CD4+ declines. Other 
distressing emotions such as sadness, anger, and anxiety were not related to CD4+ 
outcomes in this study, suggesting that there is something unique about the experience of 
shame that can produce detriments to immune function. In a later review summarizing the 
Weitzman results, the co-authors stated that “…these findings support the premise that 
shame, experienced in response to possession of a stigmatizing condition, is an important 
predictor of disease-relevant immunological change (Dickerson et al., 2004, p. 1209).” 
Like HIV, HPV has been found to be stigmatizing in those diagnosed with the virus due 
to the fact that it is a sexually transmitted infection (Massi et al., 2004). Therefore, 
persistent shame experiences in HPV patients may very well be associated with declines 
in CD4+ cells, and these are among the cells shown to be vital in the clearance of HPV 
cervical lesions (Coleman et al., 1994).   
Comparison with Epstein-Barr Virus (EBV)  
 Over 90 percent of individuals will be infected with Epstein-Barr Virus (EBV), 
and the infection will persist through the course of a person’s lifetime (Cohen, 2000). 
Most infected individuals will never develop symptoms of infection, but exposure to 
EBV in adolescence or adulthood can cause infectious mononucleosis (IM), which 
generally presents as a series of symptoms such as fever, swollen glands, and pharyngitis 
 
6 
(Straus et al., 1993).  The cell-mediated immune response in the body is primarily 
credited with the control of EBV infection. Natural killer cells, CD4+ and CD8+ 
cytotoxic T-cells are responsible for controlling primary infection of EBV, and HLA-
restricted cytotoxic T-cells are important in controlling the virus after the acute infection 
and preventing recurrence of infectious symptoms (Cohen, 2000).   
 Like HPV, EBV can remain in its host over the course of its lifetime, and the 
body relies heavily on the immune system for suppression. Unlike HPV, however, 
diagnosis of EBV or IM does not cause considerable social stigma in adults. EBV is 
contracted by the exchange of saliva, which is common after two people share eating 
utensils or drink after one another (Straus et al., 1993). Using patients recently diagnosed 
with EBV as a comparison group to measure shame and guilt experiences allows one to 
rule out the possibility that these emotions can be produced by mere diagnosis of a non-
curable virus. By comparing emotional reactions to HPV with those of EBV, there will be 
a stronger argument for the social stigma attached to HPV as the likely cause of shameful 
experiences.  
Summary 
To date, there is relatively little quantitative research on the psychosocial sequelae 
of HPV diagnosis. The research that exists suggests that diagnosis is often associated 
with emotional distress, feelings of stigmatization, and decreased sexual satisfaction 
(Kahn et al., 2007, Maissi et al., 2004).  Negative self-evaluative emotions, especially 
experiences of shame, have been showed to be markedly high in patients recently 
diagnosed with HPV (Maissi et al., 2004). Not only are individuals with HPV 
experiencing shame after learning about their diagnosis, but research has shown that 
individuals continue to feel shameful about their disease months to years after the initial 
experience (Clark et al., 1996). In other words, shame is a common and enduring 
experience in HPV diagnosis. Shame experiences related to HPV diagnosis not only have 
psychological and behavioral implications, but they can also have implications for 
disease progression. Cell mediated immune responses, most notably CD4+ activity, are 
thought to be a vital component of HPV regression and cervical lesion clearance. 
However, research has shown that persistent feelings of shame (such as the ones shown 
to endure during and after HPV diagnosis) are related to declines in CD4+ cells. 
Therefore, it is quite possible this psychological–immunological link may play a vital 
role in the disease course of HPV.  
 Some studies have speculated that providing patients with adequate knowledge 
regarding the prevalence of HPV, treatment, and actual risk of cancer can reduce 
patients’ distress (Kahn et al., 2007). However, this claim has not been empirically 
demonstrated in the literature using actual HPV patients. The current study explored the 
experience of shame and guilt among individuals diagnosed with HPV, and examined 
whether factual knowledge of HPV is related to these emotions. It was thought that if 
knowledge of HPV prevalence and risk could reduce shame and guilt in HPV patients, 
then low-cost educational interventions may be effective in improving patients’ 
psychological and biological outcomes. 
Hypotheses 
Hypothesis (1). The primary prediction was that women with HPV related-CIN 
will experience significantly more feelings of shame and guilt than women diagnosed 
with EBV, but that guilt and shame proneness would not differ between diagnoses.   
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Hypothesis (2a). It was also predicted that women with HPV-related CIN will 
have higher depression and disease-specific distress scores than women with EBV.  
Hypotheses(2b). Based on work by Orth and colleagues (2006) where shame was 
related to depression due to event-specific rumination, it was predicted that the 
relationship between HPV diagnosis and depression would be at least partially mediated 
by state-shame but not by state-guilt. The same prediction was tested for the relationship 
between HPV diagnosis and disease-specific distress.  
 Hypothesis (3). Finally it was predicted that increased knowledge of disease risk, 
etiology and transmission (of HPV or EBV, depending on the group) would be 
significantly and negatively related to feelings of shame and guilt in CIN patients but that 
no such relationship would exist in EBV patients given a psychometrically equivalent 
knowledge measure (see appendices G and H for measures).  
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Section Two: Method  
Participants 
Participants were female college students (ages 18-28), who were recently 
diagnosed with an abnormal pap smear indicating HPV related CIN (test group) and 
female students in the same age range recently diagnosed with Epstein-Barr Virus 
(comparison group). A power analysis indicated that for the hierarchical linear regression 
models, 77 participants would be needed to reach 80% power with a predicted effect size 
of r = 0.30 (a medium effect size, Cohen, 1988) and an error rate of α = 0.05. Previous 
research (Clarke et al., 1996) suggests that shame is a common experience after HPV 
diagnosis; therefore, a medium to large effect size was predicted.  The current study 
recruited 80 participants (40 in each group). Power calculations for other analyses (i.e., t-
tests and correlations) reveal that 68 participants were needed for 80% power at d = 0.7, 
α = 0.05.  
Procedure 
Participants were females recently diagnosed with HPV-related CIN (n = 40), or 
infectious mononucleosis (n = 40).  Participants were recruited through the University 
Health Services, the UK Women’s Health Clinics, and the community.  Patients were told 
by the clinic staff that they were eligible to participate in a research study, and if they 
indicated that they were interested in participating they were contacted by the researcher.  
Once contacted, the patient was told that she was eligible to participate in a research 
study on experiences after diagnosis of CIN/infectious mononucleosis, and an 
appointment time was scheduled to complete the study at place of her convenience. Some 
patients chose to complete the study at the clinic after their initial appointment. After 
informed consent was obtained, the patient was asked to complete a questionnaire packet 
containing the pertinent measures. After completion of the questionnaire packet, 
participants were paid and thanked for their time.  
Flyers advertising a confidential study on HPV/infectious mononucleosis 
experiences were also posted throughout the cities of Lexington and Richmond Kentucky 
in local gynecology offices and women’s health clinics. Participants who called about the 
study were assessed for eligibility and scheduled for participation at a time and place 
convenient to them. Recruitment took place from July 2009 to January 2010.  
Measures 
 Demographic Information Sheet. Participants first completed an information sheet 
that asked them to provide demographic information such as age, race, and ethnicity. 
Other items included insurance type, student status, relationships status, and household 
income (see appendix A).  
Guilt and Shame Proneness Scale. The GASP is a 20 item measure with two 
subscales measuring guilt-proneness as negative behavior-evaluations (α = .54) and 
approach responses following private behaviors (α = .83), and two subscales measuring 
shame proneness as negative self-evaluations (α = .69) and avoidance responses 
following public behaviors (α = .78) 1
Examples of items from the GASP include “You secretly commit a felony. What 
is the likelihood that you would feel remorse about breaking the law?” and “You take 
office supplies home for personal use and you are caught by your boss. What is the 
  (Cohen, Wolf, Panter, & Insko, 2009).   
                                                 
1 Reliability estimates were calculated from the data in the current study. 
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likelihood that you would replace what you broke?” Each item is measured on a scale of 
1(very unlikely) to 7(very likely). As predicted by Cohen et al. (2009), the guilt subscales 
were significantly correlated (r = 0.54, p < .001), but the shame subscales were not, (r = 
0.14, p > .05); therefore, the guilt subscales were collapsed to yield a total guilt proneness 
score, raising the reliability estimate to an acceptable level (.81), (M = 5.31, SD = 1.03). 
Both shame subscales were retained separately for subsequent analyses (see appendix B).  
 State Shame and Guilt Scale (SGSS). The SGSS is a 15 item scale that measures 
state guilt, shame and pride (Marschall, Sanftner, & Tangney, 1994). The authors 
discovered that the scale consists of three 5 item subscales for assessing shame (α = .89), 
guilt (α = .82), and pride (α = .87) in the moment.  This measure was developed to assess 
state emotions and does not rely on respondent’s ability to distinguish between the words 
‘shame’ and ‘guilt.’  Items that measure shame include a component of the global self 
such as: “I feel worthless, powerless.” Guilt items include a behavioral component such 
as: “I feel bad about something that I have done.” Each item is measured on a scale from 
1 (not feeling this way at all) to 5 (feeling this way very strongly). The pride subscale was 
not used in the analyses. Patients were instructed to take a minute and think about their 
recent diagnosis of HPV-related CIN or EBV-related IM before responding to these items 
(see appendices C and D). 
 Five items measuring disease specific shame and 8 items measuring behavioral 
indicators of shame were added to the scale. Disease specific shame included items such 
as “I feel like my body is damaged” and “I now feel like I no one will ever love me 
because of my diagnosis.” These items were rated on the same 1 to 5 scale as the original 
SSGS items. Behavioral shame indicators asked the respondent to rate on a scale of 1 
(extremely unwilling) to 5 (extremely willing) how willing they would be to perform such 
behaviors as “Tell my current/future partner I have HPV/EBV” and “Talk to sororities on 
campus about my experience with HPV/EBV.”  
 The estimated reliabilities for the original SSGS shame and guilt subscales in the 
current study were high (α = .92) and (α = .91), respectively. Estimates of the reliability 
coefficient for the added disease specific shame (M = 2.50, SD = 1.28), (α = 0.93) and 
behavioral shame (M = 2.49, SD = 0.98), (α = 0.88), subscales were also high2
 Center for Epidemiological Studies Depression Scale (CES-D). Some research 
has indicated that shame may overlap with symptoms of depression (Orth et al., 2006). 
Therefore, the current study included the CES-D in order to understand the potential 
relationships between these two constructs. The CES-D short form is a 10 item self-report 
measure that assesses depressive symptomatology in the general population. Examples of 
items from the CES-D short form include “I felt hopeful about the future” and “People 
were unfriendly.” Each item is scored on a response scale from 0 (rarely or none of the 
time) to 3 (all of the time). Psychometric evaluation of the CES-D short from has 
supported its validity and reliability (α = .85), and it correlates highly with longer scales 
of clinical depression symptoms (Radloff, 1977). The reliability for this measure in the 
. The 
correlations between all of the SSGS shame subscales were significant (see Table 2.1); 
therefore, these subscales were collapsed to yield a total shame score (α = .95), (M = 
2.37, SD =0 .98).  
                                                 
2 Items for the behavioral shame scale were reverse-scored in analyses, due to the fact that low scores 
indicated an unwillingness to perform the potentially shameful behavior. 
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current study was also adequate3
 Impact of Event Scale (IES) – Revised. It is possible that shame and guilt may be 
partially explained by the overlap with the stress caused by the event of diagnosis itself. 
The IES-R was included to understand the potential relationships between these two 
constructs along with depression (see above). The IES-R is a 22 item scale that measures 
intrusion (α = .86), avoidance (α = .87), and hyper-arousal (α = .85)
 (α = .85), and a total scale score was created by 
summing the score of all items for each participant (M = 9.14, SD = 6.11) (see appendix 
E).  
4
                                                 
3 Items 3 and 6 were reverse scored 
4 Reliabilities given were calculated with the data from the current study 
 due to a specific 
event, which in this study was disease diagnosis (Weiss & Marmar, 1996). The original 
IES only contained 15 items and the subscales measuring intrusion and avoidance 
(Horowitz, Wilner, & Alvarez, 1979). Examples of items from the IES include “Any 
reminder brought back feelings about it” and “I had waves of strong feelings about it”. 
Items were measured on a scale of 0 (not at all) to 4 (extremely). The three subscales 
were significantly and highly correlated (r’s > .69, p’s < .01) (see Table 2.2), therefore a 
total scale score was created using the item sum total (M = 21.71, SD = 17. 57), (α =.94). 
Using this sum score rather than the specific subscales is an accepted technique and gives 
an overall picture of event-specific distress (Weiss & Marmar, 1996) (see appendix F). 
HPV and EBV Knowledge Index. A 14 item measure was created to assess HPV 
knowledge. Eleven items were taken from a previously validated knowledge measure 
created by Kahn et al. (2003). This measure contains items that assess knowledge 
regarding HPV transmission, detection, and treatment in a true/false format. Two items 
were added to assess knowledge regarding HPV’s direct relation to genital warts and 
cervical cancer, and one additional item was added to assess knowledge of a vaccine to 
prevent cervical cancer. A parallel measure was created for the Epstein-Barr Virus, 
assessing knowledge of EBV’s transmission, detection, and treatment. There is also an 
item pertaining to EBV’s direct relation to Infectious Mononucleosis (IM). Both 
measures contained an item assessing knowledge of disease diagnosis rate (see 
Appendices G and H). 
HPV Health Index. Participants diagnosed with HPV were given a health index 
questionnaire that assessed date of diagnosis, previous. STI infections, and subjective 
knowledge of HPV. This measure was included in order to confirm that individuals met 
the criteria for participation as having a new abnormal pap smear diagnosis within the last 
two months. Subjective knowledge was strongly correlated with actual knowledge, 
indicating HPV participants were accurately aware of their own understanding of HPV (r 
= .65, p < .01) (see appendix I).   
 
 
 
 
 
 
Copyright © Sarah E. Flynn, 2010 
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Table 2.1 
Correlations Between the SSGS Shame Subscales 
 
Subscale  Disease   Behavioral       ________________ 
Behavioral  0.65** 
State   0.88**   0.61** 
Note. *p<.01 
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Table 2.2 
Correlations Between the IES Subscales 
 
Subscale  Intrusion  Avoidance       ___________ ____ 
Avoidance  .78** 
Hyperarousal  .80**   .69** 
Note. *p <.01 
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Section Three: Results 
Demographic Information 
 The current study consisted of 80 women recently diagnosed with HPV-related 
CIN (n = 40) and EBV related IM (n = 40). The average age of the participants was 21.39 
years (SD = 2.95). Participants were predominantly Caucasian (81%), but the sample also 
included women with other race/ethnic backgrounds: African American (10%), Hispanic 
(6%), and other (1%). One person in the sample did not indicate her racial/ethnic 
background.  There were no differences between the diagnoses for ethnicity χ ²(1, N = 80) 
= .24, p = .62, relationship status χ ²(3, N = 80) = 4.01, p =.26, education level χ ²(4, N = 
80) = 2.08, p = .72, type of insurance χ ²(2, N = 80) = 3.63, p =.16, or income, t(76) = -
1.93, p = .06. There was a significant difference between the two diagnoses in student 
status, where there were more graduate students in the HPV group (40% vs. 28%), and 
more undergraduate students in the EBV group (60% vs. 5%) χ ²(3, N = 80) = 8.16, p < 
.05. Although student status differed between groups, there was no significant difference 
between the groups in age t(78) = .42, p = .68.  
Hypothesis (1): Group Differences in Shame and Guilt 
 As predicted, women diagnosed with HPV (M = 2.94, SD = 0.97) had 
significantly higher state shame scores than women diagnosed with EBV (M = 1.80, SD = 
0.60), t(78) = 6.34, p < .05, d =1.14. Similarly, women with HPV (M = 2.08, SD = 1.00) 
had higher state guilt scores than women with EBV (M = 1.57, SD = .92), t(78) = 2.40),  
p < .05, d = 0.53. These results were also consistent across subscales (all p’s < .05, all d’s 
> 0.2). However, the two groups did not differ in either the negative evaluation or 
avoidance scales measuring shame proneness (t(78) = -1.26, p = .40 and t(78) =  0.02, p 
=.48) or the total scale measuring guilt proneness (t(78) = .01, p = .94) (all d’s < 0.2), 
signifying that there is something unique about HPV diagnosis that elicits these negative 
affective emotions. 
 The within subjects differences between shame and guilt were also significant for 
women with HPV t(39) = 6.01, p < .001 as well as the women with EBV t(39) = 2.08, p  
< .05) (see above analysis for means and standard deviations). This result suggests that 
shameful experiences were more prevalent than guilt experiences for both groups.   
Hypothesis (2a): Group Differences in Depression and Disease-Specific Distress 
Women with HPV (M = 11.15, SD = 6.42) had higher CES-D scores than women 
with EBV (M = 7.13, SD = 5.10), t(78) = 3.10, p < .05, d = 0.69. This pattern was also 
present for disease-specific distress scores, where women with HPV (M = 27.95, SD = 
17.12) had higher scores on the IES than women with EBV (M = 15.47, SD = 2.51), t(78) 
= 3.38, p < .01, d = 1.02.  
 These results make it difficult to understand whether depression and disease-
specific distress are a direct consequence of HPV diagnosis, or if shame and guilt mediate 
the direct effect between these variables (see Table 3.1 for correlations). To test these 
theoretical models (see figures 1 & 2), meditational analyses were conducted using the 
bootstrapping method for multi-mediator models developed by Preacher and Hayes 
(2008).  
Hypothesis (2b): Mediational Relationships between Negative Affect, Depression, and 
Disease-Specific Distress 
The first model tested the effect of diagnosis status on depression with state 
shame and guilt scores as the mediating variables. This model showed a significant 
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relationship between diagnosis status and shame (where HPV diagnosis predicted shame) 
(a1 path), B = -1.14, p < .01, between shame and depression (b1 path), B = 5.01, p < .01, 
between diagnosis and guilt (a2 path), B = -0.52, p < .05. However, the relationship 
between guilt and depression (b2 path) was not significant, B = 0.79, p = .13. The 95% 
bootstrapping confidence intervals for the indirect effects (ab1 and ab2
  The second model tested the effect of diagnosis status on disease-specific distress 
with state shame and guilt scores as the mediating variables. Both a
 paths) were 
significant for shame (-8.13 to -3.69) indicating partial mediation, but not for guilt (-1.14 
to 0.31). The relationship between HPV diagnosis and depression can be partially 
explained by shame but not by guilt (see Figure 3.1). Moreover, guilt was shown to be 
unrelated to depression in the model.  
1 and a2 paths were 
identical to model 1 (above). The relationship between shame and disease-specific 
distress (b1 path) was significant, B = 10.45, p < .001, as was the relationship between 
guilt and disease-specific distress (b2 path) B = 5.19, p < .01. The 95% bootstrapping 
confidence intervals for the indirect effects (ab1 and ab2 
Hypothesis (3): State Shame, State Guilt, and Disease Knowledge 
paths) were significant for shame 
(-19.12 to -6.29) indicating partial mediation, but not for guilt (-6.24 to 0.41). The 
relationship between HPV diagnosis and disease-specific distress can be partially 
explained by shame but not by guilt (see Figure 3.2). 
 Hierarchical linear regression analyses were conducted to test the relationship 
between HPV diagnosis and knowledge on state shame and guilt. It was predicted that 
diagnosis status (HPV or EBV) and disease knowledge would predict a significant 
amount of variance in both shame and guilt, and that there will be a significant group by 
knowledge interaction on affect, where shame and guilt will be significantly lower in the 
HPV group if knowledge of the disease is high. The total state shame score from the 
SSGS was regressed onto diagnosis status and total disease knowledge scores in the first 
step (R²∆ = 0.37), and also onto their interaction in the second step (R²∆ = .00, R²tot = 
.37).  The same procedure was conducted for guilt step 1 (R²∆ = .07), step 2 (R²∆= .08, 
R²tot
 Because previous literature has suggested that prevalence information may reduce 
negative affect associated with HPV diagnosis, identical regression analyses were 
conducted using item 15 on the knowledge index “What percentage of women will be 
diagnosed with HPV/EBV in their lifetime?” as the knowledge predictor. Total shame 
scores from the SSGS were regressed onto diagnosis status and item 15 in the first step 
(R²∆ = .40) and onto their interaction in the second step (R²∆ = 0.02, R²
 = .16). The effect of knowledge on shame was not significant (β = -0.23, p > .05); 
neither was the effect of knowledge of guilt (β = 0.19, p > .05).  The interaction between 
diagnosis status and knowledge on shame was not significant, (β = .06, p > .05) (see 
Table 3.2); neither was the interaction between diagnosis status and knowledge on guilt, 
(β = -0.29, p > .05) (see Table 3.3), failing to support the study’s third hypothesis. 
tot 
 
= .42). The 
effect of knowledge on shame was significant (β = -0.60, p < .05), where increased 
prevalence knowledge predicted decreases in shameful emotion.  This effect was not 
present for guilt (β = 0.29, p > .05). The interactions between diagnosis status and 
knowledge where also not significant for shame (β = 0.43, p > .05) or guilt (β = -0.26, p > 
.05) (see Tables 3.4 & 3.5). 
Copyright © Sarah E. Flynn, 2010 
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Table 3.1  
Correlations Between Diagnosis, Knowledge, Shame, Guilt, Depression and Distress 
 
Variable             Diagnosis    State Shame    State Guilt   IES-R  CES-D  Knowledge Prevalence  GuiltProne                            
State Shame     -.58**   
State Guilt     -.26*          .60**  
IES     -.36**         .73**            .63**    
CES-D     -.32**         .79**            .60**        .80** 
 Knowledge         .04        -.20           -.08       -.09        -.09  
Prevalence Item        .11           -.21              .04       -.12         -.25*          .14              
Guilt Prone      .14         .09    .30**          .16           .04            .10             .21 
Shame Prone (apb)  -.02         .01                -.05       -.09          .02           -.01             .05    .14 
Shame Prone (nse)    .14         .01                 .09        .13          .05             .06 .09    .57** 
Note. *p < .05, **p < .01; HPV = 0, EBV = 1 
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Table 3.2 
Hierarchical Linear Regression Model for Diagnosis X Total Knowledge on Shame 
 
             R           Rsq.       Rsq. Δ  __Beta        partial r      p-value_ 
Model 1       .61        .37             .37     ___ 
Diagnosis                -.57       -.59     <.01 
Total Knowledge______         -.18       -.22       .52____ 
Model 2      .61         .37  .00______________________________ 
Diagnosis            -.58      -.59     <.01              
Total Knowledge           -.23      -.09       .39 
Diagnosis X Knowledge           .06        .02                .84____ 
Note: HPV = 0, EBV = 1 
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Table 3.3 
Hierarchical Linear Regression Model for Diagnosis X Total Knowledge on Guilt 
 
             R           Rsq.       Rsq. Δ  _Beta        partial r      p-value__ 
Model 1       .27        .07   .07     ____            
Diagnosis                -.51       -.26      .21 
Total Knowledge______            -.07       -.07      .52_____ 
Model 2      .29         .08  .01_______________________________ 
Diagnosis            -.26      -.26      .02 
Total Knowledge            .19        .07      .55 
Diagnosis X Knowledge          -.29      -.10                .39_____ 
Note: HPV = 0, EBV = 1 
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Table 3.4 
Hierarchical Linear Regression Model for Diagnosis X Prevalence Knowledge on Shame 
             R           Rsq.       Rsq. Δ  __Beta        partial r      p-value___ 
Model 1       .63        .40             .40     _____ 
Diagnosis                 -.60       -.61      .21 
Total Knowledge______          -.20       -.25      .03_______ 
Model 2      .65        .42 .02_________________________________ 
Diagnosis            -.60      -.62   <.01 
Total Knowledge           -.60      -.24      .03 
Diagnosis X Knowledge           .43       .17                .13_______ 
Note: HPV = 0, EBV = 1 
 
 
 
 
 
 
 
 
 
 
 
19 
Table 3.5 
Hierarchical Linear Regression Model for Diagnosis X Prevalence Knowledge on Guilt 
             R           Rsq.       Rsq. Δ  __Beta        partial r      p-value_ 
Model 1       .30        .09             .09    _________ 
Diagnosis                -.30       -.30      .01 
Total Knowledge______          .04        .04      .72____ 
Model 2      .32         .10  .01______________________________ 
Diagnosis            -.30     -.30         .01 
Total Knowledge            .29       .01      .41 
Diagnosis X Knowledge          -.26     -.09                 .45____ 
Note: HPV = 0, EBV = 1  
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Figure 3.1 
The Relationship between HPV Diagnosis and Depression with Shame and Guilt as 
Mediators 
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Figure 3.2 
The Relationship between HPV Diagnosis and Distress with Shame and Guilt as 
Mediators 
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Section Four: Discussion 
Summary 
Recent literature has suggested that diagnosis of HPV can lead to persistent 
experiences of distress, most notably shame and guilt, as well as perceived social threat 
(Clark et al., 1996; Kahn et al., 2007; Maissi et al., 2004). Not only does HPV diagnosis 
impact psychosocial functioning, but these negative self-conscious emotional states have 
been associated with compromised immune function. In several studies, persistent shame 
was related to declines in CD4+ cells (Dickerson et al., 2004). These cells have shown to 
be vital in the clearance of HPV lesions. The current study also found that shame was 
responsible for the relationships between HPV diagnosis and depression/distress.For 
these reasons, it is important to investigate how to reduce negative self-conscious 
emotions, particularly shame, in women diagnosed with HPV.  Some research has 
suggested that increases in HPV knowledge may mitigate negative affective experiences 
such as shame (Kahn et al., 2007; Waller et al., 2007), especially knowledge related to 
the high rates of diagnosis. The primary goal of this study was to understand how 
knowledge of HPV diagnosis would affect feelings of shame in guilt in a sample of 
recently diagnosed young women. 
Women ranging in age from 18 to 28 who were recently diagnosed with HPV-
related cervical intraepithelial neoplasia (CIN) were given measures of shame and guilt 
proneness, state shame and guilt, depression, disease-specific distress, and HPV 
knowledge.  A comparison group of women recently diagnosed with Infectious 
Mononucleosis (IM) due to Epstein-Barr Virus (EBV) were also given identical 
measures, including EBV-specific knowledge.  
Hypothesis (1): Group Difference in Shame and Guilt 
 As predicted, women with HPV  reported greater shame and guilt than women 
diagnosed with EBV. Women diagnosed with HPV had higher incidence of both state 
shame and guilt than women diagnosed with EBV, supporting the first hypothesis and 
results of previous studies. The strength of this result can be bolstered in this study due to 
the inclusion of a comparison group of women diagnosed with an immunologically-
similar disease. This was the first study of its kind to use this type of comparison 
condition. Additionally, the differences in negative affect between the groups were not 
due to individual differences in shame and guilt proneness, suggesting that there is 
something unique about the experience of being diagnosed with HPV that elicits this 
negative self-directed affect. 
Hypothesis (2a): Group Differences in Depression and Disease-Specific Distress 
 Women with HPV had higher levels of both depression and disease-specific 
distress as indicated on the CES-D and IES-R, respectively. One possibility for these 
differences could be that HPV diagnosis leads to feelings of depression and lingering 
distress from the impact of diagnosis, which in turn spark negative self-directed affective 
states such as shame and guilt. Another possibility is that HPV diagnosis directly leads to 
negative self-directed affect, which in turn leads to depressive and distressful states.  
Hypothesis (2b):Mediational Relationships between Negative Affect, Depression, and 
Disease-Specific Distress 
The latter model (above) has been supported in other stressful life events, such as 
a marital separation (Orth et al., 2006). It was predicted that the relationship between 
HPV diagnosis and depression would be mediated by shame but not by guilt. The same 
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result was predicted for the relationship between HPV diagnosis and disease-specific 
distress. 
In order to test these theoretical models (see figures 1 & 2), mediational analyses 
were  using the multi-mediator bootstrapping method (Preacher & Hayes, 2008).  The 
results suggested that shame partially mediated the relationship between HPV diagnosis 
and both depression and disease-specific distress, but this was not true for guilt. 
Moreover, in the first model, the path between guilt and depression was not significant, 
indicating that guilt was unrelated to depression in the model. These results are in line 
with previous research that has suggested that shame overlaps with depression, but guilt 
does not (Orth et al., 2006).   
We can argue from the results of these mediational tests that HPV diagnosis can 
lead to negative psychological states such as depression and distress, but it does so 
through shameful experiences. Guilt, on the other hand, cannot account for the 
relationship between diagnosis and these negative states. Not only is shame responsible 
for a decline in important immunological parameters (Dickerson et al., 2004), but the 
results from this study show it is also related to detriments in psychosocial functioning.  
Hypothesis (3): State Shame, State Guilt, and Disease Knowledge 
 It was also predicted that knowledge would moderate the diagnosis-shame 
relationship, where increases in disease knowledge would lead to decreases in negative 
affective states (i.e., shame and guilt) in women diagnosed with HPV, but that no such 
relationship would exist in EBV patients. This hypothesis was not supported in the 
current study for total disease knowledge. However, when the specific item “What 
percentage of women will be diagnosed with HPV/EBV in their lifetime?” from the 
knowledge questionnaire was used in the regression model, there was a significant main 
effect for knowledge but no significant interaction. Increases in this percentage predicted 
lower shame scores overall, but did not do so differentially by diagnosis status. There 
were no significant effects for guilt using this item.  
HPV Diagnosis: The Role of Knowledge 
Literature continues to suggest that HPV diagnosis is related to negative affective 
states, including shame. One study by Waller, Marlow, and Wardle (2007) suggested that 
increases in HPV knowledge, such as levels of prevalence, decrease feelings of shame 
and perceived stigma. However, this study only asked individuals to imagine that they 
were diagnosed with HPV. The current effort was the first known study using actual HPV 
patients to test this hypothesis. Even though knowledge of higher disease preference rates 
did predict shame, it did so for both HPV and EBV patients. It may be reasonable to 
suggest that information regarding high prevalence rates for any disease d iagnosis may 
decrease shameful emotions, as increased prevalence may decrease the possibility for 
stigma.   
In contrast to their previous study, Waller and colleagues (2009) found that HPV 
information actually increased anticipated shame and worry, although this was most 
apparent in non-white ethnic groups and individuals with lower levels of education. 
These competing results, along with the results of the current study, suggest that the 
relationship between HPV knowledge and negative affect is still largely unclear. 
Researchers do agree, however, that levels HPV-related knowledge remain low in 
the general population, even after the introduction of the Gardasil vaccine (Wong & Sam, 
2010). Moreover, research continues to suggest that healthcare providers continue to give 
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incomplete or unclear information to their patients regarding HPV and cervical cancer 
(Cermak, Cotrell, & Murnan, 2010). Even though the relationships between HPV 
knowledge and affect are still ambiguous, it is important for individuals to understand the 
transmission and etiology of HPV in order increase preventative behaviors such as 
vaccination (Devereaux Walsh, Gera, Shah, Sharma, Powell & Wilson, 2008). HPV 
knowledge may also improve screening adherence (Miller, Micshel, O’Leary & Mills, 
1996). 
Limitations and Future Directions 
 The cross-sectional design of the current study made it difficult to determine the 
causal mechanisms between HPV, knowledge, shame. With a larger sample size, a 
structural equation model could have been used to evaluate pathways and compare the fit 
of these data to the two theoretical models proposed in this study. It is also worth noting 
that a longitudinal design would provide even greater evidence regarding the causal 
nature of these relationships.  Nevertheless, this study suggested that the relationship 
between HPV diagnosis and negative psychological states such as depression and distress 
were partially explained by shameful experiences.   
 Shame’s relation to decreased CD4+ cells and negative psychosocial functioning 
such as depression and distress should continue to be the driving force for future 
research, considering shame is an enduring aspect of HPV diagnosis (Clark et al, 1992).  
Decreasing shameful experiences may give women with HPV a better disease prognosis, 
as CD4+ cells are vital in the clearance of HPV lesions (Coleman et al., 1994). Measuring 
immune parameters may be a way to understand how HPV-related shame contributes to 
disease progression. Moreover, improvement in psychological functioning may improve 
HPV prognosis through treatment adherence.  
Conclusions 
 This study was able to show that HPV diagnosis is related to negative affective 
states such as shame and guilt. Because this study used a comparison group of women 
diagnosed with another viral illness, it can be concluded that the HPV experience is 
inimitable. Shame‘s relationship to HPV is much more broad and complex than guilt, as 
it is the mediating variable between the diagnosis and negative psychological states such 
as depression and disease-specific distress.  
 Shame’s relationship to negative psychosocial outcomes may also have 
subsequent behavioral consequences in HPV diagnosis. It may be possible that persistent 
shame experiences would decrease preventative behaviors and treatment adherence. If 
shame decreases the likelihood of future screening behavior, than increases in cervical 
cancer morbidity and mortality would result.   
There are competing theories of how knowledge of HPV affects affective states 
(Maissi et al., 2004; Waller et al., 2007; Waller et al., 2009). This study was unable to 
show that knowledge mitigated HPV-related shame. However, knowledge of disease 
prevalence decreased shame in both groups, which may suggest that providing adequate 
knowledge to patients may still be beneficial, especially if it increases prevention 
behaviors or adherence to treatment guidelines. 
 
 
Copyright © Sarah E. Flynn, 2010 
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Appendix A: Demographic Information Sheet 
 
Age: ________ (years)      
 
Ethnicity:      Highest level of education completed 
□Non- Hispanic     □Some high school 
□Hispanic      □High school or GED   
Race:       □Some college 
□Hispanic      □Bachelor’s Degree 
□Caucasian        □Graduate or Professional Degree 
□African Descent  What type of health insurance do you have? 
□Asian             □ Private health insurance         
□Native American    □ Medicare/Medicaid 
□Other____________________________ □I do not have health insurance    
 
Relationship Status:   Estimated yearly household income  
□ Single         □ less than $10,000 per year 
□ Serious Relationship   □ $10,001 - $20,000 per year 
□ Married      □ $20,001 - $40,000 per year 
□ Separated     □ $40,001 - $60,000 per year 
□ Other  ________________  □ $60,001 - $80,000 per year 
      □ greater than $100,000 per year 
      □ $80,001 - $100,000 per year 
 
Current student status:    
□ Undergraduate     
□ Graduate or Professional School   
□ non-student - employed    
□ non-student – unemployed      
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Appendix B: GASP 
Instructions: In this questionnaire you will read about situations that people are likely to 
encounter in day-to-day life, followed by several common reactions to those situations. 
As you read each scenario, try to imagine yourself in that situation. Then indicate the 
likelihood that would react in the way described. 
1 2 3 4 5 6 7 
Very 
Unlikely 
Unlikely Slightly 
Unlikely 
About 
50% 
Likely 
Slightly 
Likely 
Likely Very 
Likely 
_______ 1. After realizing you have received too much change at a store, you decide to 
keep it because the salesclerk doesn't notice. What is the likelihood that you would feel 
uncomfortable about keeping the money?   
_______ 2. You are privately informed that you are the only one in your group that did 
not make the honor society because you skipped too many days of school. What is the 
likelihood that this would lead you to become more responsible about attending school?  
_______ 3. You rip an article out of a journal in the library and take it with you. Your 
teacher discovers what you did and tells the librarian and your entire class. What is the 
likelihood that this would make you would feel like a bad person?  
_______ 4. After making a big mistake on an important project at work in which people 
were depending on you, your boss criticizes you in front of your coworkers. What is the 
likelihood that you would feign sickness and leave work?  
_______ 5. You reveal a friend’s secret, though your friend never finds out. What is the 
likelihood that your failure to keep the secret would lead you to exert extra effort to keep 
secrets in the future? 
_______ 6. You give a bad presentation at work. Afterwards your boss tells your 
coworkers it was your fault that your company lost the contract. What is the likelihood 
that you would feel incompetent?  
_______ 7. A friend tells you that you boast a great deal. What is the likelihood that you 
would stop spending time with that friend?  
_______ 8. Your home is very messy and unexpected guests knock on your door and 
invite themselves in. What is the likelihood that you would avoid the guests until they 
leave?  
_______ 9. You secretly commit a felony. What is the likelihood that you would feel 
remorse about breaking the law?  
1 2 3 4 5 6 7 
Very 
Unlikely 
Unlikely Slightly 
Unlikely 
About 
50% 
Likely 
Slightly 
Likely 
Likely Very 
Likely 
_______ 10. You successfully exaggerate your damages in a lawsuit. Months later, your 
lies are discovered and you are charged with perjury. What is the likelihood that you 
would think you are a despicable human being?  
_______ 11. You strongly defend a point of view in a discussion, and though nobody was 
aware of it, you realize that you were wrong. What is the likelihood that this would make 
you think more carefully before you speak.  
_______ 12. You take office supplies home for personal use and are caught by your boss. 
What is the likelihood that this would lead you to quit your job? 
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_______ 13. Because of your carelessness, you break something you borrowed from a 
friend, though your friend never notices. What is the likelihood that you would replace 
what you broke?  
_______ 14. You make a mistake at work and find out a coworker is blamed for the error. 
Later, your coworker confronts you about your mistake. What is the likelihood that you 
would feel like a coward?  
_______ 15. You make a strong argument in a debate but the moderator points out to 
everyone that your facts are incorrect. What is the likelihood that you would feel like an 
idiot?  
_______ 16. You falsify some information in a job application though it is never 
discovered. What is the likelihood that you would feel that the way you acted was 
despicable?  
_______17. While you are out with friends, someone you knowingly deceived tells your 
friends that you are a liar. What is the likelihood that you would quickly leave and go 
home?  
_______ 18. At a coworker’s housewarming party, you spill red wine on their new 
cream-colored carpet. You cover the stain with a chair so that nobody notices your mess. 
What is the likelihood that you would feel that the way you acted was pathetic?  
_______ 19. While discussing a heated subject with friends, you suddenly realize you are 
shouting though nobody seems to notice. What is the likelihood that you would try to act 
more considerately toward your friends? 
_______ 20. You lie to people but they never find out about it. What is the likelihood that 
you would feel terrible about the lies you told? 
 
You are finished with this section. Please turn the page and continue. 
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Appendix C: SSGS-HPV 
 
Take a minute and think about your recent abnormal pap smear that indicated that you 
had cervical dysplasia caused by HPV.  The following are some statements that may or 
may not describe how you are feeling RIGHT NOW.  Please rate each statement using 
the 5 point scale below. Remember to rate each statement based on how you are feeling 
RIGHT AT THIS MOMENT. 
           Not feeling                             Feeling                    Feeling this 
      this way at all                 this way somewhat          way very strongly 
     
1.  I feel good about myself.   1-------------2------------3------------4----------5 
 
2.  I want to sink into the floor  
     and disappear.   1-------------2------------3------------4----------5 
 
3.  I feel remorse, regret.   1-------------2------------3------------4----------5 
 
4.  I feel worthwhile, valuable.  1-------------2------------3------------4----------5 
 
5.  I feel small.    1-------------2------------3------------4----------5 
 
6.  I feel tension about something 
     I have done.    1-------------2------------3------------4----------5 
 
7.  I feel capable, useful.   1-------------2------------3------------4----------5 
 
8.  I feel like I am a bad person.  1-------------2------------3------------4----------5 
 
9.  I cannot stop thinking about  
     something bad I have done.  1-------------2------------3------------4----------5 
 
10.  I feel proud.    1-------------2------------3------------4----------5 
 
11.  I feel humiliated, disgraced.  1-------------2------------3------------4----------5 
 
12.  I feel like apologizing,  
       confessing.    1-------------2------------3------------4----------5 
 
13.  I feel please about something 
       I have done.     1-------------2------------3------------4----------5 
 
14. I feel worthless, powerless.  1-------------2------------3------------4----------5 
 
15. I feel bad about something 
      I have done.    1-------------2------------3------------4----------5 
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16. I feel like my body is 
      damaged.     1-------------2------------3------------4----------5 
 
17.  I feel others would treat me  
       differently if they knew about 
       my diagnosis.   1-------------2------------3------------4----------5 
 
18.  I feel like I’m now part of a 
       stigmatized group of people. 1-------------2------------3------------4----------5 
 
19.  I feel like no one will ever love 
       me because of my diagnosis. 1-------------2------------3------------4----------5 
 
20.  I feel like others will see 
       me as damaged.   1-------------2------------3------------4----------5 
 
 
________________________________________________________________________ 
 
 
Please rate each statement below as an indicator of how WILLING you would be to do 
the following:      
      Extremely             Somewhat     Extremely 
                Unwilling                           Willing                     Willing 
 
1. Tell my friends I have HPV……..  1-------------2------------3------------4----------5 
 
2. Tell a family member  
    I have HPV……….………………1-------------2------------3------------4----------5 
  
3. Tell my current/future 
     partners that I have HPV……….. 1-------------2------------3------------4----------5 
 
4. Tell another healthcare provider  
    that I have HPV………………… . 1-------------2------------3------------4----------5 
  
5. Talk to a group of high-school 
    students about my experience  
    with HPV. ...................................... 1-------------2------------3------------4----------5 
  
6. Talk to sororities on campus about  
    my experience with HPV……….. . 1-------------2------------3------------4----------5 
  
7.  Attend a support group for  
     women diagnosed with HPV……. 1-------------2------------3------------4----------5 
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8. Have my picture and my HPV  
    status featured in an advertisement 
    for HPV prevention…………….... 1-------------2------------3------------4----------5 
You are finished with this section. Please turn the page and continue. 
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Appendix D: SSGS-EBV 
Take a minute and think about your recent diagnosis of Infectious Mononucleosis “mono” that 
caused by exposure to the Epstein-Barr Virus (EBV). The following are some statements that 
may or may not describe how you are feeling RIGHT NOW. Please rate each statement using 
the 5 point scale below. Remember to rate each statement based on how you are feeling RIGHT 
AT THIS MOMENT. 
           
      Not feeling              Feeling       Feeling this 
       this way at all                    this way somewhat         way very strongly 
     
1.  I feel good about myself.   1----------------2--------------3--------------4--------------5 
 
2.  I want to sink into the floor  
     and disappear.   1----------------2--------------3--------------4--------------5 
 
3.  I feel remorse, regret.   1----------------2--------------3--------------4--------------5 
 
4.  I feel worthwhile, valuable.   1----------------2--------------3--------------4--------------5 
 
5.  I feel small.     1----------------2--------------3--------------4--------------5 
 
6.  I feel tension about something 
     I have done.     1----------------2--------------3--------------4--------------5 
 
7.  I feel capable, useful.   1----------------2--------------3--------------4--------------5 
 
8.  I feel like I am a bad person.   1----------------2--------------3--------------4--------------5 
 
9.  I cannot stop thinking about  
     something bad I have done.   1----------------2--------------3--------------4--------------5 
 
10.  I feel proud.    1----------------2--------------3--------------4--------------5 
 
11.  I feel humiliated, disgraced.  1----------------2--------------3--------------4--------------5 
 
12.  I feel like apologizing,  
       confessing.    1----------------2--------------3--------------4--------------5 
 
13.  I feel please about something 
       I have done.     1----------------2--------------3--------------4--------------5 
 
14. I feel worthless, powerless.   1----------------2--------------3--------------4--------------5 
 
15. I feel bad about something 
      I have done.    1----------------2--------------3--------------4--------------5 
 
16. I feel like my body is 
      damaged.     1----------------2--------------3--------------4--------------5 
 
17.  I feel others would treat me  
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       differently if they knew about 
       my diagnosis.   1----------------2--------------3--------------4--------------5 
 
18.  I feel like I’m now part of a 
       stigmatized group of people. 1----------------2--------------3--------------4--------------5 
 
19.  I feel like no one will ever love 
       me because of my diagnosis. 1----------------2--------------3--------------4--------------5 
 
20.  I feel like others will see 
       me as damaged.   1----------------2--------------3--------------4--------------5 
 
 
______________________________________________________________________________ 
 
 
Please rate each statement below as an indicator of how WILLING you would be to do the 
following:  
      Extremely                  Somewhat          Extremely 
                Unwilling                                 Willing                             Willing 
 
1. Tell my friends I have EBV……..  1----------------2--------------3--------------4--------------5 
 
2. Tell a family member  
    I have EBV……….……………… 1----------------2--------------3--------------4--------------5 
  
3. Tell my current/future 
     partners that I have EBV………..  1----------------2--------------3--------------4--------------5 
 
4. Tell another healthcare provider  
    that I have EBV………………… . 1----------------2--------------3--------------4--------------5 
  
5. Talk to a group of high-school 
    students about my experience  
    with EBV. ...................................... 1----------------2--------------3--------------4--------------5 
  
6. Talk to sororities on campus about  
    my experience with EBV………..  1----------------2--------------3--------------4--------------5 
  
7.  Attend a support group for  
     women diagnosed with EBV.…..  1----------------2--------------3--------------4--------------5 
  
8. Have my picture and my EBV  
    status featured in an advertisement  
    for EBV prevention……………... 1----------------2--------------3--------------4--------------5 
 
 
 
 
 
You are finished with this section. Please turn the page and continue. 
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Appendix E: CES-D Short Form 
 
Below is a list of some ways you may have felt or behaved. Please indicate how often you have felt this 
way during the PAST WEEK: (check  ONE number on each line). 
 
Rarely or 
none of the 
time 
(Less than 1 
day) 
 
 
0 
Some or a 
little of the 
time 
(1-2 days) 
 
 
 
1 
Occassionally 
or a 
moderate 
amount of 
time 
(3-4 days) 
 
2 
All of the 
time 
 
(5-7 days) 
 
 
 
3 
During the Past Week…. 
 
1.  I was bothered by things that             □          □         □          □   
     usually don’t bother me………………...................0          1                        2                         3     
 
2. I felt that I could not shake off the blues      □          □         □          □ 
    even with help from my family…………………....0           1                       2                         3     
 
3.  I felt that I was just as good   □          □         □          □      
     as other people………………………………….....0           1                  2              3      
 
4.  I had trouble keeping my mind on    □          □         □          □ 
     what I was doing……………………………….......0           1                  2            3 
 
5.  I felt that everything I did was     □          □         □          □       
     an effort………………………………………………0           1                   2            3 
 
        □          □         □          □ 
6.  I felt hopeful about the future……………………….0           1                        2                         3 
 
                                                                         □          □         □          □ 
7.  I thought my life had been a failure……………..….0          1                  2                         3 
 
        □          □          □          □ 
8.  I felt fearful………………………….………………0          1                      2           3 
 
             □          □          □          □ 
9.  I felt lonely………………………………………….0          1                     2            3 
          □          □          □          □ 
10.  People were unfriendly……………..……………..0          1             2            3 
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Appendix F: IES Revised 
Below is a list of difficulties people sometimes have after stressful life events. Please 
read each item, and then indicate how distressing each difficulty has been for you 
DURING THE PAST SEVEN DAYS with respect to your diagnosis, how much were 
you distressed or bothered by these difficulties? 
 Not at all 
A little 
bit Moderately 
Quite a 
bit Extremely 
Any reminder brought back 
feelings about it 0 1 2 3 4 
I had trouble staying asleep 0 1 2 3 4 
Other things kept making me 
think about it 0 1 2 3 4 
I felt irritable and angry 0 1 2 3 4 
I avoided letting myself get 
upset when I thought about it or 
was reminded of it 
0 1 2 3 4 
I thought about it when I didn’t 
mean to 0 1 2 3 4 
I felt as if it hadn’t happened or 
wasn’t real 0 1 2 3 4 
I stayed away from reminders 
about it 0 1 2 3 4 
Pictures about it popped into my 
mind 0 1 2 3 4 
I was jumpy and easily startled 0 1 2 3 4 
I tried not to think about it 0 1 2 3 4 
I was aware that I still had a lot 
of feelings about it, but I didn’t 
deal with them 
0 1 2 3 4 
My feelings about it were kind 
of numb 0 1 2 3 4 
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I found myself acting or feeling 
as though I was back at that time 0 1 2 3 4 
I had trouble falling asleep 0 1 2 3 4 
I had waves of strong feelings 
about it 0 1 2 3 4 
I tried to remove it from my 
memory 0 1 2 3 4 
I had trouble concentrating 0 1 2 3 4 
Reminders of it caused me to 
have physical reactions, such as 
sweating, trouble breathing, 
nausea, or a pounding heart 
0 1 2 3 4 
I had dreams about it 0 1 2 3 4 
I felt watchful or on-guard 
  
0 1 2 3 4 
I tried not to talk about it 0 1 2 3 4 
 
 
 
 
 
 
 
 
You are finished with this section. Please turn the page and continue. 
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Appendix G: HPV-KQ 
 
Please circle the correct response to each question as either TRUE or FALSE. 
 
1.  A person may be infected with HPV and not know it.   TRUE   FALSE 
 
2.  Those with HPV may need pap smears more often.  TRUE  FALSE 
 
3.  HPV is spread by sexual intercourse.    TRUE  FALSE 
 
4.  Pap smears can detect HPV.     TRUE  FALSE 
 
5.  HPV can be cured with antibiotics.    TRUE  FALSE 
 
6.  HPV causes abnormal menstrual periods.   TRUE  FALSE 
 
7.  Smoking increases the chance of developing cervical cancer. TRUE  FALSE 
 
8.  Condoms do not help protect you from HPV.   TRUE  FALSE 
 
9.  HPV goes away with the right treatment.   TRUE  FALSE 
 
10. Certain types of HPV always cause cancer.   TRUE  FALSE  
 
11.  HPV can cause problems with pregnancy.   TRUE  FALSE 
 
12.  HPV is the leading cause of genital warts.   TRUE  FALSE 
 
13.  HPV can cause cervical cancer.    TRUE  FALSE 
 
14.  Some types of HPV can be prevented with a vaccine. TRUE  FALSE 
 
 
Approximately what percentage of women will contract HPV by the time they reach the age of 50 
years old? __________% 
 
 
 
 
You are finished with this section. Please turn the page and continue 
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Appendix H: EBV-KQ 
 
Please circle the correct response to each question as either TRUE or FALSE. 
1.  A person may be infected with Epstein-Barr Virus (EBV) 
     and not know it.      TRUE  FALS E  
2. A blood test can detect EBV    TRUE  FALSE 
3.  EBV is spread by the exchange of saliva.   TRUE  FALSE 
4.  EBV can be cured with antibiotics.   TRUE  FALSE 
5.  Exposure to EBV always causes a person to develop 
      infectious mononucleosis or “mono”.   TRUE  FALSE 
6.  Children rarely get mono from EBV.     TRUE  FALSE 
7.  EBV goes away with the right treatment.   TRUE  FALSE 
8.  EBV can cause swollen glands and a sore throat.  TRUE  FALSE 
9.  Covering your cough helps prevent the spread of EBV. TRUE  FALSE 
10.  EBV can cause problems with your spleen.  TRUE  FALSE 
11. People with EBV can show symptoms for months at a time.  
TRUE  FALSE 
12. Smoking increases the chances of developing mono. TRUE  FALSE  
13. EBV has been associated with some types of cancer. TRUE  FALSE 
14. Some types of EBV can be prevented with a vaccine. TRUE  FALSE 
 
Approximately what percentage of people will contract EBV in their lifetime? 
_________% 
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Appendix I: Health Index - HPV 
 
1.  How many days has it been since you were told about your diagnosis of HPV? 
____________ 
 
2.  Have you ever been diagnosed with a previous Sexually Transmitted Infection?   
□YES  
□NO 
 
3.  Have you ever previously had an abnormal pap smear?  
□YES  
□NO 
 
4.  If so, when? ____________________ 
 
5.  Have you ever been diagnosed with HPV before this time?  
□YES  
□NO 
 
Please circle ONE NUMBER to indicate your response. 
 
6.  How would you rate your knowledge of HPV? 
I have no knowledge              I am very knowledgeable  
         0  1  2  3  4  5  
 
7.  How much research did you do on HPV after learning about your diagnosis?   
I did no research       I researched it a lot 
         0  1  2  3  4  5  
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